1269773-69-4

Upstream product

• 790-75-0 N-(3,5-bis-trifluoromethyl-phenyl)-2-chloro-acetamide 
• 57260-71-6 1-t-Butoxycarbonylpiperazine 
• 99468-72-1 N-[3,5-bis(trifluoromethyl)phenyl]-2-bromoacetamide 
• 328-74-5 3,5-Bis-(trifluoromethyl)aniline 

Downstream Products

• 1269773-40-1 N-(3,5-bis(trifluoromethyl)phenyl)-2-(piperazin-1-yl)acetamide hydrochloride 
• 1401333-74-1 C₂₂H₂₃F₆N₃O 
• 1401333-72-9 C₂₁H₂₁F₆N₃O 

Relevant academic research and scientific papers

The design and synthesis of 1,4-substituted piperazine derivatives as triple reuptake inhibitors

Novel 1,4-substituted piperazine derivatives 5, Series A and B were designed by fragment analysis and molecular modification of 4 selected piperazine-containing compounds which possess antidepressant activity. We synthesized new 39 analogues of Series A and 10 compounds of Series B, respectively. The antidepressant screening against DA, NE, and serotonin neurotransmitter uptake inhibition was carried out using the Neurotransmitter Transporter Uptake Assay Kit. The compounds in Series B showed relatively higher reuptake inhibitory activity for SERT, NET, and DAT than those in Series A. The length of spacer between the central piperazine core and the terminal phenyl ring substituted at the piperazine ring in Series B seems to exert an important role in the activity.

SUBSTITUTED HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF PAIN AND EPILEPSY

Compounds of formula (I) which are useful in ameliorating conditions characterized by unwanted sodium and/or calcium channel activity, particularly unwanted Nav 1.7, Nav 1.8, or Cav 3.2 channel activity are disclosed. Specifically, a series of compounds containing piperidine or piperazine linked through an amide, isoxazole or similar linker to an aryl ring are described and are shown to be useful for the treatment of pain or epilepsy. A is selected from Formulae (i) or (ii).